Igc Pharma, Inc. · AMEX:IGC
Igc Pharma — Investor Presentation (April 2025)
28 slides from Igc Pharma's investor presentation, April 2025
Slide 1: IGC Pharma 2025
= \. IGCPHARMA NYSE AMERICAN: IGC 2025
Slide 2: Safe Harbor
Safe Harbor The matters discussed in this presentation include forward-looking statements about the business prospects of IGC Pharma, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes, or similar expressions.
Slide 3: Highlights
Highlights Diversified pipeline containing multiple patent protected Alzheimer’s Disease (AD) candidates and new GLP-1 candidates IGC-AD1 near-term opportunity with Phase 2 CALMA trial in agitation – the only natural THC-based investigational drug candidate currently undergoing FDA trials Long-term
Slide 4: Highlights
Highlights Leading artificial intelligence partnerships Poised for growth with industry headwinds from Complementary & Alternative Medicine (CAM) Market Vertically Integrated manufacturing and production facilities Clean capital structure NYSE American: IGC
Slide 5: IGC is Well Positioned in Two Large Addressable Markets
IGC is Well Positioned in Two Large Addressable Markets Alzheimer’s Complementary and Alternative Therapeutics Market1 Medicine Market1 $15.2B1 $1.2T2 Market Size in 2030 Market Size in 2033 19.99% 25% CAGR 2023- 2030 CAGR 2024- 2033 $4.2B $123.8B Market Size in 2022 Market Size in 2023 1 Grandview
Slide 6: Our Pipeline
Our Pipeline Asset Preclinical Phase I Phase II Phase III Milestones Interim Phase 2 IGC-AD1 Targets NPS and AD pathology data available Bio Equivalence to LMP-platform Targets NPS and AD pathology IGC-AD1 2025 TGR-platform Targets Aβ plaques (Early- Moderate AD) Tox study 2025 IGCM-platform Targets
Slide 7: Protected Intellectual Property
Protected Intellectual Property Patent US Patents Foreign Patents Target Target Description Description Applications Granted Granted (IGC-AD1) Composition & Method for treating CNS Disorders. 7 1 (IGC-AD1) Composition & Method for treating CNS Disorders. 8 1 1 (TGR-63) Naphthalene Monoimide Derivati
Slide 8: Primary Target: Therapeutic Treatment for Agitation in Alzheimer's
Primary Target: Therapeutic Treatment for Agitation in Alzheimer’s Agitation: excessive motor activity, verbal aggression, or physical aggression impairing personal relationships, social functioning, and/or daily activities Agitation starts early in AD and increases in severity as the disease progre
Slide 9: IGC-AD1
The Only “Treatment” Option Today Our Solution REXULTI® (brexpiprazole) IGC-AD1 • A repurposed, atypical A natural patent-protected compound antipsychotic with a in Phase 2B trials black box warning • Costing patients The FIRST compound that relies on low $17,000 per year with a doses of THC, a cann
Slide 10: IGC-AD1 Phase 2 CALMA Trial: Ongoing
IGC-AD1 Phase 2 CALMA Trial: Ongoing Multicenter, Double Blind, Randomized, Placebo-Controlled Trial Objectives: Evaluate the safety and efficacy of IGC- AD1 on agitation in AD at week 2 and week 6 Key Inclusion Criteria: The study targets completion by 146 participants Diagnosis of probable AD usin
Slide 11: Phase 2 Interim Results Indicate Drug Could Outperform Current Approved Therapy
Phase 2 Interim Results Indicate Drug Could Outperform Current Approved Therapy CMAI score: Cohen-Mansfield Agitation Inventory, a clinical tool used to assess and quantify agitation levels In this study, patients who took IGC-AD1 showed a statistically significant improvement vs placebo in agitatio
Slide 12: Adverse Events: IGC-AD1 vs. Brexpiprazole
Adverse Events: IGC-AD1 vs. Brexpiprazole Brexpiprazole Trial IGC-AD1 Trial to date • ~6% participants had SAEs No SAEs reported up to 6 weeks • 5% participants had AEs leading to discontinuation No AEs leading to discontinuation • 7 deaths reported, 6 in the No deaths active group and 1 in placebo
Slide 13: Secondary Target: IGC-AD1 as a Disease Modifying Treatment
Secondary Target: IGC-AD1 as a Disease Modifying Treatment ~400 million 50 million 7 million Asymptomatic with Diagnosed with Americans currently AD pathology in their AD worldwide2 living with AD2 brains1 1Baylor University, October 2024 22024 Alzheimer's disease facts and figures. Alzheimer's Deme
Slide 14: Our Preclinical Data
Our Preclinical Data IGC-AD1 inhibits Aβ plaque production by ~40% Non-disruptive to Amyloid Precursor Protein (APP) Reduces pTau/Tau implicated in tangles Improves spatial memory in APP/PS1 mouse model by 50% *Results from N2a/AbetaPPswe Alzheimer’s cell lines J. Pineal. Res. 2011, 51, 75-86; J. Al
Slide 15: Phase 2 Mini Mental State Exam (MMSE) Interim Results
Phase 2 Mini Mental State Exam (MMSE) Interim Results MMSE scores MMSE, 30-point test, assess global 0.8 cognitive status. LS Mean Change from Baseline 0.6 It is widely used to detect cognitive 0.4 impairment IGC-AD1 0.2 No negative impact on cognitive Δ= 0.9 performance compared to placebo 0 -0.2 P
Slide 16: Revenue Projections for Agitation in Alzheimer's
Revenue Projections for Agitation in Alzheimer’s North America And Europe Adoption Adoption Adoption Item Individuals with AD 15 million 15 million 15 million Agitation in AD (76%) 11 million 11 million 11 million % adoption of IGC-AD1 3% 5% 10% Monthly Price of drug $700 $700 $700 Estimated $2.7B $
Slide 17: Next 18 months for IGC-AD1
Next 18 months for IGC-AD1 1. Data read out for completed Phase 2 trial as a treatment for Agitation in AD 2. Seek FDA approval with potential commercialization, through compassionate use 3. Complete partial toxicology studies for IGC-AD1 for chronic use 4. Establish IGC-AD1 as a disease- modifying
Slide 18: Potential Valuation Milestones
Potential Valuation Milestones $4B Valuation $300m, $500m, 1.2B Valuation Path to exponential value creation: Current valuation is ~ $30m • Near-term clinical advancement • Expanding market opportunity ~ $30m as disease modifying treatment Enterprise Value Complete one of two today Complete Phase 2
Slide 19: TGR Platform
TGR Platform NYSE American: IGC
Slide 20: TGR-63 Ameliorates Aβ Plaque
TGR-63 Ameliorates Aβ Plaque IGC licensed TGR from India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) Preclinical data testing demonstrates TGR-63 holds TGR-63 potential to ameliorate plaque Behavioral tests with AD (APP/PS1) mice show that TGR-63 can: • Rescue neuronal ce
Slide 21: The Promise of TGR-63: Reduction of Plaque in Mouse Model
The Promise of TGR-63: Reduction of Plaque in Mouse Model Before administration TGR-63 Administration After administration AD/WT characterization Behavioral study Immunohistochemistry 14m 0m 6m TGR-63 effectively reduced the amyloid WT Vehicle WT TGR-63 AD Vehicle AD TGR-63 burden in the mice cortex
Slide 22: AI-Powered Pharmaceutical Innovation
AI-Powered Pharmaceutical Innovation
Slide 23: AI Powered Model for Alzheimer's
AI Powered Model for Alzheimer’s IGC is building a Foundation Model for Alzheimer’s that can help predict early markers and disease progression using data from around the world The model will be deployed on the web for doctors to use as a tool to help diagnose early Alzheimer’s NYSE American: IGC
Slide 24: Strategic Expansion into Metabolic Disorders
Strategic Expansion into Metabolic Disorders Leveraging AI-driven insights, IGC Pharma is expanding its portfolio to include GLP- 1 agonists Expansion into GLP-1 therapies allows IGC to tap into the multi- billion-dollar global market for weight management and type-2 diabetes treatments, while maint
Slide 25: Scientific Advisors
Scientific Advisors Chemistry and Pharmaceutical Sciences Psychiatry and AI Prof. Joseph Prof. Chuanhai Prof. T. Prof. Elliot Prof. James Prof. Jeffrey Prof. Pablo Fortunak, Cao, Govindaraju, Hong, Saunders, Cummings, Arbelaez, PhD PhD PhD, FRSC. MD PhD MD, ScD, Chair of the PhD Professor Professor
Slide 26: Science Team
Science Team Internal CRO to conduct and manage clinical trials Dr. Juanita Arbeláez, Evelyn Gutiérrez, Dr. Juan Orjuela, MD Diego Rodriguez, Ph.D. Building a synthesis Neuropsychiatrist MD, MPH Medical Director Eng. MPH CRO Manager Senior Chemist lab Partnered with manufacturers and top universitie
Slide 27: Executive Management & Board
Executive Management & Board Executive management Board Ram Mukunda, Claudia Grimaldi Richard Prins Ex. Congressman Terry Lierman CEO, Director VP & Director Chairman James Moran Director Director Board Advisors Governor Amb. (Rtd) Terry McAuliffe Howard Gutman NYSE American: IGC
Slide 28: Thank you
Join Us in The Fight to Conquer Alzheimer’s Thank you Ram Mukunda • ram@igcpharma.com www.igcpharma.com Claudia Grimaldi NYSE AMERICAN: IGC • cgrimaldi@igcpharma.com